



COLORADO MEDICAID PRESCRIPTION DRUG PROGRAM DUR BOARD MEETING

February 25, 2014

6:00 p.m. Closed Executive Session for Board Members

7:00 p.m. – 9:00 p.m. Open Session

225 16th Avenue, Denver 80203

1st floor conference room

Agenda items must be approved in advance, including requests to present information.

Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item.

Visitors are welcome during the open portion of the meeting only.

AGENDA

Executive Session (Closed)

- Approval of the minutes from the previous meeting
- Review Retro-DUR reports
- Quarterly Drug Utilization Reports
- Approval of Retro DUR Criteria
- FDA updates
- Review of Opioid Module Data

Open Session

Unfinished Business and General Orders

- Approval of minutes from the November 2013 Meeting minutes
- Update on the following:
 - Oral Fluoroquinolones
 - Oral Anti-Herpetic Agents
 - Pancreatic Enzymes
 - Newer Antiplatelet Agents
 - Self-administered Targeted Immune Modulators
 - Newer Generation Antidepressants
 - Pulmonary Hypertension Agents (PDE inhibitors, Prostanoids, Endothelin Antagonists)
 - Proton Pump Inhibitors
 - Triptans
 - Oral Anticoagulants

New Business

- Proposed Criteria for current PDL:
 - Insulins
 - Alzheimer's agents
 - Atypical antipsychotics
 - Growth hormones
 - Intranasal corticosteroids
 - Leukotriene modifiers
 - Multiple Sclerosis agents

- Ophthalmic allergy
- Sedative/hypnotics (non benzodiazepine)
- Statins and Statin combinations
- Proposed Criteria for Other Agents:
 - Opioids
 - Lidoderm
 - Kynamro
 - Farxiga
 - Hepatitis C medications

- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.